Pharmaceuticals

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts

 EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility inWaltham, Massachusetts to fur...

2025-08-25 12:01 1072

Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform

 * The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results,?showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...

2025-08-22 18:14 2004

MALAYSIA SHOWCASES HEALTHCARE EXCELLENCE IN CAMBODIA, DRIVING MOMENTUM TOWARDS MYMT 2026

 KUALA LUMPUR, Malaysia, Aug. 22, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) proudly presents Malaysia Healthcare Week 2025 inPhnom Penh, Cambodia, an initiative designed to strengthening healthcare ties between the two nations and positionMalaysia as the medical tourism de...

2025-08-22 11:00 2414

Biosyngen Unveils Innovative Strategies for Next-Generation TIL Therapies in Asia Bio 2025 Singapore

 SINGAPORE, Aug. 22, 2025 /PRNewswire/ -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events inAsia and focus on the hottest topics of?ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from...

2025-08-22 09:55 2396

Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results

 Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled:? Eng...

2025-08-21 18:02 2567

Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!

TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical , a leader in novel drug delivery systems, will attend the upcomingNACDS Total Store Expo  (TSE), where it will spotlight its proprietary WINMAP? microarray patch (MAP) technology and laun...

2025-08-21 09:23 1321

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

 MELBOURNE, Australia?and?INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...

2025-08-21 08:23 2146

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

 CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based o...

2025-08-20 08:00 2143

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

 CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...

2025-08-19 20:09 1265

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

 SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...

2025-08-19 13:26 1283

Beyfortus? (nirsevimab) approved in Singapore to protect all infants against RSV disease

 * Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent?HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...

2025-08-19 11:00 2142

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

 YANTAI, China, Aug. 19, 2025 /PRNewswire/ --?RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...

2025-08-19 08:00 1331

Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

 * This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...

2025-08-18 21:00 1364

KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

 * Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...

2025-08-18 18:29 1901

New support group to provide social and community support for neurofibromatosis patients

 Co-founded by individuals living with this rare genetic condition, the? Neurofibromatosis Society Singapore seeks to close gaps in mental and emotional care SINGAPORE, Aug. 18, 2025 /PRNewswire/ --?A new patient-led support group, the Neurofibromatosis Society (NFS)Singapore, has been recently re...

2025-08-18 09:00 1619

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

 Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that?etrasimod (VELSIPITY?) has be...

2025-08-15 09:35 1645

TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future

 BOSTON, Aug. 14, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with itsOrchestration Platfor...

2025-08-14 22:00 1546

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

 NANJING, China, Aug. 14, 2025 /PRNewswire/ --?Nanjing Leads?Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LB...

2025-08-14 17:38 1463

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY? by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

 SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that?the Taiwan Food and Drug Adminis...

2025-08-14 12:02 1523

Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

 * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects?1 in 4 people globally (1.2 billion), with?188 million patients in India—most undiagnosed until irr...

2025-08-14 08:00 1434
12345 ... 190